We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Alexion

News List

Alexion price cut opens up Strensiq to more patients pharmaphorum
July 06, 2017
NICE has recommended Strensiq in a wider group of patients with the ultra-rare disease paediatric-onset hypophosphatasia, after Alexion agreed a price cut.
Alexion submits application to Japan’s MHLW to extend Soliris indication to treat gMG pharmaceutical-technology
March 27, 2017
Alexion Pharmaceuticals has submitted an application to extend the indication for Soliris (eculizumab) as a potential treatment for patients with refractory generalised myasthenia gravis (gMG).
Alexion forecasts Soliris growth for 2017 in wake of probe into sales practices firstwordpharma
February 17, 2017
Alexion Pharmaceuticals on Thursday said that it anticipates Soliris sales in 2017 in the range of $3.03 billion to $3.1 billion, in line with analyst estimates. The therapy amassed about $2.8 billion in revenue for last year, compared to $2.6 billion in

Previous page 1 2 3 4 5 Next page